Aktana Status
The company raised $21.07 million of Series C venture funding from undisclosed investors on September 26, 2018, putting the company's pre-money valuation at $93.62 million.
Developer of a decision support platform that synthesizes and prioritizes data to provide commercial teams relevant insights and suggested actions within their workflows. The company's platform harnesses machine learning algorithms, analyzes market data, channel activity and HCP preference in real-time, enabling pharmaceutical companies to increase revenue, capitalize on data investments, and drive channel productivity and results.
Year Founded
2008
Employees
120
General Information
-
Website
-
Business Status
Generating Revenue
-
Ownership Status
Privately Held (backing)
-
Financing Status
Venture Capital-Backed
Aktana News and Updates
How to build flexibility into a modern global commercial model – PharmaLive
PharmaLive | June 15, 2022
Almirall rolls out sales rep artificial intelligence system, cutting pre-call prep and 'windshield time'
Endpoints News | May 25, 2022
Safeguard Scientifics Announces First Quarter 2022 Financial Results
GlobeNewswire | May 5, 2022
Almirall Deploys Aktana's Contextual Intelligence 360 to Optimize Customer Engagement
Business Wire | May 4, 2022
Safeguard Scientifics Announces Full Year And Fourth Quarter 2021 Financial Results
GlobeNewswire | March 9, 2022
How to design an omnichannel AI ecosystem for optimum customer engagement
MedCity News | February 22, 2022
Aktana's Feed
Aktana's Verticals
Aktana Primary Industry Sector / Group / Code
Aktana's Trends
Aktana Metrics
Growth Rate
SimilarWeb Unique Visitors
Majestic Referring Domains
Twitter Followers
Headquarters
-
HQ Address Line 1207 Powell Street
-
HQ Address Line 28th Floor
-
HQ CitySan Francisco
-
HQ State/ProvinceCalifornia
-
HQ Post Code94102
-
HQ CountryUnited States
Aktana's Keywords
Add a review